NEW YORK, Nov. 6 — A division of Thermo Electron and Paradigm Genetics have formed a partnership to design new technologies for use in metabolomics, also known as the study of the interactions between small molecules, the companies said on Tuesday.
The companies plan to use chromatography and mass spectrometry systems to develop a new way to identify and validate metabolite biomarkers that they believe may be useful in drug discovery.
Under the terms of the arrangement, Paradigm, of Research Triangle Park, NC, will provide technical consulting services in exchange for exclusive pre-commercial access to new systems made by Thermo Finnigan. Paradigm, which is publicly owned, specializes in functional genomics and metabolic profiling technologies.
Financial terms of the agreement were not disclosed.
Thermo Finnigan, based in Waltham, Mass., specializes in mass spectrometers, chromatography systems, related software, and multi-instrument combinations of these products.
The companies did not disclose any further financial details of the agreement.